Skip to main content
Search
Search
Advanced Search
Skip main navigation
Skip slideshow

How are life sciences organizations creating value from real-world data?

Senior leaders from Novo Nordisk, Bayer, Johnson & Johnson, and Takeda discuss how to move RWD from a supporting resource to a genuine strategic asset.

Read here

MFN one year on: Taking stock of US drug pricing reform

Tim Wright revisits the predictions he made following the Executive Order, examines what has materialized, and considers the future for GENEROUS, GUARD and GLOBE.

Read here

Innovation without access? The growing tension in rare disease coverage

Discussions from the World Orphan Drug Congress USA 2026.

Read here

WEBINAR: An HEOR playbook for oncology RWE and AI use to support European HTA

How oncology RWD and AI-enabled evidence generation can strengthen EU HTA submissions under JCA.

Register here

VIDEO: How to build real-world evidence that survives regulatory scrutiny

Xabier García de Albéniz, Adigens Health, discusses the design choices that often determine whether an observational study withstands scrutiny.

Watch here

Evaluating modular reference models for early oncology economic evaluation

A modular oncology reference model designed to support early economic evaluation in oncology, using a case study in EGFR-mutated NSCLC.

Read here

News

Deep Dives

WEBINARS

EXPERT INSIGHTS

Interested in learning more about our sponsorship opportunities?
Click here

SPOTLIGHTS

Most-Favored Nation
Most-Favored-Nation
JCA
JCA in Europe
ISPOR 2026
Interested in the Journal of Comparative Effectiveness Research?
Click here
Health Economics
Health Economics
Health Technology Assessment
Health Technology Assessment
Real World Evidence
Real-World Evidence
market access
Market Access